Cellular therapy is a relatively new treatment option, which contributes to significant advancements in technology and genetic research (Vaquero, Hassan, Fernandez, Rodriguez & Zurita, 2017). Cell transplantation with mesenchymal stromal cells via injection into the site of the syrinx shows potential in the future treatment of syringomyelia without surgery (Vaquero et al. 2017).
To our knowledge, only one study has examined the use of cellular therapies for the treatment of syringomyelia. Vaquero et al. (2018) had a small patient sample of six, however they were able to observe strong improvements in spinal cord function at three and six months post-injection. Unfortunately, in terms of outcomes measuring bladder and bowel dysfunction no significant differences were reported. More studies are required on the use of cellular therapy as a potential non-surgical treatment for syringomyelia before any substantial conclusions can be drawn.
There is level 4 evidence (from one pre-post study; Vaquero et al., 2018a) that mesenchymal stromal cell therapy may be effective in improving spinal cord function post-SCI.
Further research is needed to determine the potential benefits of cellular therapy for the treatment of syringomyelia.